Q20001556263--12-31false0001556263syrs:EmployeeStockPurchasePlan2016Member2016-07-060001556263syrs:ConleyCheeMember2024-04-012024-06-300001556263syrs:TermLoanAndSecurityAgreementMember2020-02-120001556263us-gaap:RetainedEarningsMember2023-03-310001556263syrs:GlobalBloodTherapeuticsMemberus-gaap:CollaborativeArrangementMember2024-01-012024-06-300001556263us-gaap:RetainedEarningsMember2024-06-300001556263syrs:TermLoanAndSecurityAgreementMembersyrs:SecondLoanTrancheMember2022-09-300001556263us-gaap:CommonStockMember2023-04-012023-06-3000015562632024-06-300001556263syrs:TermLoanAndSecurityAgreementMember2024-05-092024-05-090001556263syrs:JasonHaasMember2024-04-012024-06-300001556263syrs:HQLeaseMember2024-06-300001556263syrs:TymeTechnologiesIncMember2023-06-300001556263syrs:FirstDrawOfLoanAgreementMember2024-06-300001556263us-gaap:PrivatePlacementMember2024-01-012024-06-300001556263srt:MaximumMember2023-04-062023-04-060001556263us-gaap:RetainedEarningsMember2024-01-012024-06-300001556263syrs:TwentyTwentyWarrantsMemberus-gaap:PrivatePlacementMember2020-12-082020-12-080001556263us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001556263syrs:TwentyTwentyTwoWarrantsMemberus-gaap:PrivatePlacementMember2022-09-160001556263us-gaap:CommonStockMember2023-01-012023-06-300001556263syrs:EmployeeStockPurchasePlan2016Member2016-07-052016-07-060001556263syrs:TermLoanAndSecurityAgreementMember2020-02-122020-02-120001556263syrs:EmployeeAndOthersStockOptionMember2024-01-012024-06-300001556263us-gaap:DebtInstrumentRedemptionPeriodTwoMembersyrs:TermLoanAndSecurityAgreementMember2020-02-122020-02-120001556263srt:DirectorMembersyrs:RestrictedStockUnitsAndRestrictedStockAwardsMember2024-01-012024-06-300001556263syrs:SecondDrawOfTermLoanAndSecurityAgreementMember2023-06-300001556263us-gaap:AdditionalPaidInCapitalMember2023-06-300001556263us-gaap:PrivatePlacementMember2023-01-012023-06-300001556263us-gaap:RetainedEarningsMember2023-01-012023-06-300001556263us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001556263us-gaap:FairValueMeasurementsRecurringMembersyrs:CashAndMoneyMarketFundsMember2024-06-300001556263us-gaap:CommonStockMember2022-12-310001556263us-gaap:RetainedEarningsMember2024-04-012024-06-300001556263us-gaap:DebtInstrumentRedemptionPeriodThreeMembersyrs:TermLoanAndSecurityAgreementMember2020-02-122020-02-120001556263us-gaap:PrivatePlacementMembersyrs:TwentyTwentyTwoWarrantsMember2024-06-300001556263syrs:PreFundedWarrantsMember2023-06-300001556263us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001556263syrs:GlobalBloodTherapeuticsMemberus-gaap:CollaborativeArrangementMember2024-04-012024-06-300001556263syrs:UnderwrittenRegisteredDirectOfferingMembersyrs:TwentyTwentyThreePreFundedWarrantsMember2023-12-310001556263us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001556263syrs:TwoThousandTwentyTwoInducementStockIncentivePlanMember2023-01-310001556263us-gaap:AdditionalPaidInCapitalMember2024-06-3000015562632023-01-012023-12-310001556263us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001556263us-gaap:MeasurementInputPriceVolatilityMember2024-06-300001556263syrs:TermLoanAndSecurityAgreementMembersyrs:TermLoanAMember2020-02-120001556263syrs:TermLoanAndSecurityAgreementMembersrt:ScenarioForecastMember2024-05-312025-01-310001556263us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-300001556263syrs:TermLoanAndSecurityAgreementMember2024-01-012024-06-300001556263us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001556263us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001556263syrs:TermLoanAndSecurityAgreementMembersyrs:TermLoanCMember2024-06-300001556263syrs:UnderwrittenRegisteredDirectOfferingMember2023-01-012023-12-310001556263syrs:TwoThousandTwentyTwoInducementStockIncentivePlanMember2024-06-300001556263syrs:TermLoanAndSecurityAgreementMembersyrs:TermLoanBMember2020-12-230001556263us-gaap:FairValueMeasurementsRecurringMember2024-06-300001556263syrs:TermLoanAndSecurityAgreementMember2023-01-012023-06-300001556263us-gaap:FairValueMeasurementsRecurringMembersyrs:CashAndMoneyMarketFundsMember2023-12-3100015562632022-12-310001556263syrs:FourthLoanAmendmentMembersyrs:TermLoanAndSecurityAgreementMember2020-02-120001556263syrs:EmployeeAndOthersStockOptionMembersyrs:GradedVestingMember2024-01-012024-06-300001556263syrs:DavidARothMDMember2024-04-012024-06-300001556263us-gaap:CommonStockMember2024-06-300001556263us-gaap:AdditionalPaidInCapitalMember2024-03-310001556263us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001556263syrs:PrivatePlacementSeptember2022Membersyrs:PreFundedWarrantsMember2024-06-300001556263us-gaap:PrivatePlacementMember2022-09-162022-09-160001556263us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembersyrs:CashAndMoneyMarketFundsMember2023-12-310001556263us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300001556263us-gaap:RetainedEarningsMember2023-04-012023-06-300001556263syrs:CashAndMoneyMarketFundsMember2024-06-300001556263srt:MaximumMember2024-06-050001556263syrs:PrivatePlacementDecember2020Membersyrs:PreFundedWarrantsMember2024-06-300001556263us-gaap:CommonStockMember2024-04-012024-06-300001556263us-gaap:FairValueInputsLevel3Member2024-06-300001556263syrs:TermLoanAndSecurityAgreementMember2024-04-012024-06-300001556263syrs:TermLoanAndSecurityAgreementMembersrt:ScenarioForecastMember2025-02-012026-05-310001556263us-gaap:MeasurementInputExpectedTermMember2023-01-012023-12-310001556263syrs:TermLoanAndSecurityAgreementMembersyrs:TermLoanCMember2020-02-122020-02-120001556263syrs:PrivatePlacementSeptember2022Member2024-06-300001556263syrs:PrivatePlacementDecember2020Member2024-06-300001556263syrs:TermLoanAndSecurityAgreementMember2024-05-082024-05-080001556263syrs:TwentyTwentyWarrantsMemberus-gaap:PrivatePlacementMembersrt:MaximumMember2020-12-080001556263syrs:GlobalBloodTherapeuticsMemberus-gaap:CollaborativeArrangementMember2023-01-012023-06-300001556263syrs:PrivatePlacementSeptember2022Membersyrs:PreFundedWarrantsMember2023-06-300001556263srt:MinimumMembersyrs:RestrictedStockUnitsAndRestrictedStockAwardsMember2024-01-012024-06-300001556263us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2022-09-162022-09-160001556263us-gaap:PrivatePlacementMembersrt:MaximumMembersyrs:TwentyTwentyTwoWarrantsMember2022-09-160001556263us-gaap:AdditionalPaidInCapitalMember2022-12-3100015562632024-04-012024-06-300001556263syrs:HQLeaseMember2024-01-012024-06-300001556263us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001556263us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001556263syrs:December2023RegisteredDirectOfferingMembersyrs:PreFundedWarrantsMember2024-06-300001556263syrs:TwentyTwentyTwoPreFundedWarrantsMemberus-gaap:PrivatePlacementMember2022-09-160001556263us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001556263us-gaap:MeasurementInputRiskFreeInterestRateMember2024-06-3000015562632023-10-022023-10-020001556263syrs:CashAndMoneyMarketFundsMember2023-12-310001556263syrs:PrivatePlacementDecember2020Member2023-06-300001556263us-gaap:CommonStockMember2024-03-310001556263syrs:TwentyTwentyWarrantsMemberus-gaap:PrivatePlacementMember2020-12-080001556263us-gaap:FairValueInputsLevel3Member2022-12-310001556263us-gaap:AdditionalPaidInCapitalMember2023-12-310001556263us-gaap:WarrantMember2023-01-012023-06-3000015562632024-03-310001556263syrs:TwentyTwentyTwoWarrantsMemberus-gaap:PrivatePlacementMember2023-12-310001556263syrs:TermLoanAndSecurityAgreementMembersyrs:TermLoanDMember2020-02-122020-02-120001556263syrs:TwentyTwentyTwoWarrantsMemberus-gaap:PrivatePlacementMember2022-09-162022-09-160001556263syrs:TermLoanAndSecurityAgreementMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2020-02-122020-02-120001556263us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001556263syrs:TermLoanAndSecurityAgreementMembersyrs:FirstLoanTrancheMember2022-09-300001556263syrs:RestrictedStockUnitsAndRestrictedStockAwardsMember2024-06-300001556263syrs:TermLoanAndSecurityAgreementMember2024-06-300001556263us-gaap:CommonStockMember2024-01-012024-06-300001556263us-gaap:CommonStockMember2023-03-310001556263us-gaap:RetainedEarningsMember2022-12-310001556263syrs:GradedVestingMember2024-01-012024-06-300001556263syrs:TymeTechnologiesIncMember2024-06-300001556263syrs:TMRCMember2024-04-012024-06-300001556263syrs:KristinStephensMember2024-04-012024-06-300001556263us-gaap:WarrantMember2024-01-012024-06-300001556263us-gaap:AdditionalPaidInCapitalMember2023-03-310001556263syrs:TermLoanEMembersyrs:TermLoanAndSecurityAgreementMember2020-02-122020-02-120001556263syrs:TermLoanAndSecurityAgreementMember2024-05-090001556263syrs:FirstDrawOfLoanAgreementMember2023-06-300001556263syrs:PrivatePlacementDecember2020Membersyrs:PreFundedWarrantsMember2023-06-3000015562632024-01-012024-06-300001556263us-gaap:RetainedEarningsMember2023-12-310001556263syrs:OperatingLeaseOctober2023Member2024-06-300001556263us-gaap:PrivatePlacementMember2020-12-082020-12-0800015562632023-06-300001556263us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001556263us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001556263syrs:EmployeeStockPurchasePlan2016Member2024-06-300001556263us-gaap:RetainedEarningsMember2023-06-300001556263us-gaap:CommonStockMember2023-06-300001556263us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001556263us-gaap:CommonStockMember2023-12-3100015562632023-12-310001556263us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001556263syrs:TMRCMember2023-04-012023-06-300001556263us-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001556263us-gaap:MeasurementInputExpectedTermMember2024-01-012024-06-300001556263us-gaap:FairValueInputsLevel3Member2023-12-310001556263us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001556263syrs:GlobalBloodTherapeuticsMemberus-gaap:CollaborativeArrangementMember2023-04-012023-06-300001556263syrs:RestrictedStockUnitsAndRestrictedStockAwardsMember2024-01-012024-06-300001556263us-gaap:FairValueMeasurementsRecurringMember2023-12-310001556263us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-3000015562632023-04-012023-06-300001556263syrs:EmployeeStockPurchasePlan2016Member2024-01-012024-01-010001556263srt:MinimumMember2024-06-050001556263us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembersyrs:CashAndMoneyMarketFundsMember2024-06-3000015562632023-03-310001556263us-gaap:PrivatePlacementMember2023-04-012023-06-300001556263us-gaap:PrivatePlacementMember2024-04-012024-06-3000015562632023-01-012023-06-300001556263syrs:TMRCMember2024-01-012024-06-300001556263syrs:TermLoanAndSecurityAgreementMember2023-04-012023-06-300001556263us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-06-300001556263us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001556263us-gaap:MeasurementInputPriceVolatilityMember2023-12-310001556263us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001556263us-gaap:MeasurementInputSharePriceMember2024-06-300001556263syrs:TMRCMember2023-01-012023-06-300001556263us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001556263syrs:PrivatePlacementSeptember2022Member2023-06-300001556263us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001556263syrs:GeraldEQuirkEsqMember2024-04-012024-06-300001556263syrs:TwoThousandTwentyTwoEquityIncentivePlanMember2024-06-052024-06-050001556263syrs:TermLoanAndSecurityAgreementMembersyrs:TermLoanDMember2024-06-300001556263us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001556263syrs:TwoThousandTwentyTwoEquityIncentivePlanMember2024-06-300001556263us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001556263us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-06-300001556263us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2020-12-082020-12-080001556263syrs:RestrictedStockUnitsAndRestrictedStockAwardsMember2023-12-310001556263us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001556263syrs:RestrictedStockUnitsAndRestrictedStockAwardsMembersrt:MaximumMember2024-01-012024-06-300001556263syrs:TermLoanEMembersyrs:TermLoanAndSecurityAgreementMember2024-06-300001556263us-gaap:RetainedEarningsMember2024-03-310001556263syrs:TwentyTwentyPreFundedWarrantsMemberus-gaap:PrivatePlacementMember2020-12-080001556263us-gaap:MeasurementInputSharePriceMember2023-12-310001556263us-gaap:FairValueInputsLevel3Member2023-01-012023-12-310001556263syrs:SecondDrawOfTermLoanAndSecurityAgreementMember2024-06-300001556263syrs:CliffVestingMembersyrs:EmployeeAndOthersStockOptionMember2024-01-012024-06-300001556263us-gaap:FairValueInputsLevel3Member2024-01-012024-06-300001556263syrs:PreFundedWarrantsMember2024-06-300001556263syrs:GlobalBloodTherapeuticsMemberus-gaap:CollaborativeArrangementMember2023-06-300001556263syrs:TermLoanAndSecurityAgreementMember2024-05-08xbrli:purexbrli:sharessyrs:Itemsyrs:Segmentiso4217:USDxbrli:sharesiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-37813

SYROS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware

 

45-3772460

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

 

35 CambridgePark Drive, 4th Floor

Cambridge, Massachusetts

 

02140

(Address of Principal Executive Offices)

 

(Zip Code)

(617) 744-1340

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange
on Which Registered

Common Stock, $0.001 par value

 

SYRS

 

Nasdaq Global Select Market

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

 

Accelerated filer

Non-accelerated filer

 

 

 

 

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Number of shares of the registrant’s common stock, $0.001 par value, outstanding on July 26, 2024: 26,809,764

 


 

TABLE OF CONTENTS

 

Page

Part I – FINANCIAL INFORMATION

 

 

Item 1. Financial Statements (unaudited)

5

 

 

Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023

5

Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023

6

Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023

7

Condensed Consolidated Statements of Stockholders Equity (Deficit) for the Three and Six Months Ended June 30, 2024 and 2023

8

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023

10

Notes to Condensed Consolidated Financial Statements

11

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

25

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

36

 

 

Item 4. Controls and Procedures

37

 

 

Part II – OTHER INFORMATION

 

 

Item 1A. Risk Factors

38

 

 

Item 5. Other Information

39

 

 

Item 6. Exhibits

40

 

 

Signatures

40

 

2


 

Cautionary Note Regarding Forward-Looking Statements and Industry Data

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward‑looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward‑looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward‑looking statements, although not all forward‑looking statements contain these identifying words. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. The forward‑looking statements and opinions contained in this Quarterly Report are based upon information available to us as of the date of this Quarterly Report and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.

These forward‑looking statements include, among other things, statements about:

our plans to initiate and expand clinical trials of tamibarotene and our expectations for the timing, quantity and quality of information to be reported from our clinical trials of tamibarotene;
our planned clinical trials for tamibarotene or for any other product candidates, whether conducted by us or by any collaborators, including the timing of these trials and of the anticipated results;
our ability to replicate in any clinical trial of a product candidate the results we observed in preclinical or earlier clinical studies of such product candidate;
our ability to replicate in the final results of any clinical trial of one of our product candidates the results we observed in interim results of such clinical trial;
our plans to research, develop, seek approval for, manufacture and commercialize tamibarotene or any future product candidates;
our plans to develop and seek approval of diagnostic tests for use in identifying patients who may benefit from treatment with tamibarotene or any future product candidates;
our ability to enter into, and the terms and timing of, any collaborations, license agreements, asset sales, or other arrangements;
the potential benefits of any collaboration;
developments relating to our competitors and our industry;
the impact of government laws and regulations;
the timing of and our ability to file new drug applications and obtain and maintain regulatory approvals for tamibarotene or any future product candidates;
the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval;
our commercialization, marketing and manufacturing capabilities and strategy;
our intellectual property position and strategy;
our ability to identify additional products or product candidates with significant commercial potential;
our expectations related to the use of our current cash and cash equivalents and the period of time in which such capital will be sufficient to fund our planned operations;
our estimates regarding expenses, future revenue, capital requirements and need for additional financing;
our ability to secure sufficient additional capital in the near term or implement other strategies needed to alleviate our current doubt about our ability to continue as a going concern; and
general economic conditions, including inflation, recession risk and increasing interest rates.

3


 

We may not actually achieve the plans, intentions or expectations disclosed in our forward‑looking statements, and you should not place undue reliance on our forward‑looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward‑looking statements we make. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward‑looking statements contained in this Quarterly Report.

Our forward‑looking statements also do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.

This report also includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates. All of the market data used in this report involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for tamibarotene or any future product candidate include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

You should read this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward‑looking statements, whether as a result of new information, future events or otherwise, except as required by law.

4


 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

SYROS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

(unaudited)

 

 

June 30,

 

 

December 31,

 

 

 

2024

 

 

2023

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

78,964

 

 

$

139,526

 

Prepaid expenses and other current assets

 

 

5,957

 

 

 

5,454

 

Total current assets

 

 

84,921

 

 

 

144,980

 

Property and equipment, net

 

 

6,633

 

 

 

7,298

 

Other long-term assets

 

 

1,460

 

 

 

1,592

 

Restricted cash

 

 

2,119

 

 

 

2,119

 

Right-of-use asset – operating lease

 

 

11,589

 

 

 

12,185

 

Total assets

 

$

106,722

 

 

$

168,174

 

Liabilities and stockholders' (deficit) equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

7,469

 

 

$

11,544

 

Accrued expenses and other current liabilities

 

 

14,557

 

 

 

16,146

 

Operating lease obligation, current portion

 

 

2,495

 

 

 

2,324

 

Debt, current portion

 

 

 

 

 

6,667

 

Total current liabilities

 

 

24,521

 

 

 

36,681

 

Operating lease obligation, net of current portion

 

 

17,232

 

 

 

18,528

 

Warrant liabilities

 

 

30,387

 

 

 

61,747

 

Debt, net of debt discount, net of current portion

 

 

40,934

 

 

 

34,556

 

Commitments and contingencies (See Note 9)

 

 

 

 

 

 

Stockholders' (deficit) equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; 0 shares issued and outstanding at June 30, 2024 and December 31, 2023

 

 

 

 

 

 

Common stock, $0.001 par value; 140,000,000 and 70,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 26,809,764 and 26,448,678 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively

 

 

26

 

 

 

26

 

Additional paid-in capital

 

 

743,464

 

 

 

739,443

 

Accumulated deficit

 

 

(749,842

)

 

 

(722,807

)

Total stockholders' (deficit) equity

 

 

(6,352

)

 

 

16,662

 

Total liabilities and stockholders' (deficit) equity

 

$

106,722

 

 

$

168,174

 

See accompanying notes to unaudited condensed consolidated financial statements.

5


 

SYROS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2024

 

2023

 

 

2024

 

 

2023

 

Revenue

 

$

 

$

2,833

 

 

$

 

 

$

5,787

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

21,953

 

 

29,608

 

 

 

46,608

 

 

 

58,369

 

General and administrative

 

 

5,463

 

 

7,225

 

 

 

11,729

 

 

 

14,630

 

Total operating expenses

 

 

27,416

 

 

36,833

 

 

 

58,337

 

 

 

72,999

 

Loss from operations

 

 

(27,416

)

 

(34,000

)

 

 

(58,337

)

 

 

(67,212

)

Interest income

 

 

1,085

 

 

2,125

 

 

 

2,631

 

 

 

3,900

 

Interest expense

 

 

(1,382

)

 

(1,278

)

 

 

(2,689

)

 

 

(2,495

)

Change in fair value of warrant liabilities

 

 

4,386

 

 

(3,105

)

 

 

31,360

 

 

 

5,760

 

Net loss applicable to common stockholders

 

$

(23,327

)

$

(36,258

)

 

$

(27,035

)

 

$

(60,047

)

Net loss per share applicable to common stockholders - basic and diluted

 

$

(0.59

)

$

(1.30

)

 

$

(0.69

)

 

$

(2.15

)

Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted

 

 

39,269,434

 

 

27,913,448

 

 

 

39,123,740

 

 

 

27,878,030

 

See accompanying notes to unaudited condensed consolidated financial statements.

6


 

SYROS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)

(unaudited)

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net loss

 

$

(23,327

)

 

$

(36,258

)

 

$

(27,035

)

 

$

(60,047

)

Other comprehensive gain:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized holding loss on marketable securities, net of tax

 

 

 

 

 

(214

)

 

 

 

 

 

(53

)

Comprehensive loss

 

$

(23,327

)

 

$

(36,472

)

 

$

(27,035

)

 

$

(60,100

)

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

 

 

7


 

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the three months ended June 30, 2024 and 2023

(in thousands, except share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

 

 

 

Number of

 

 

Par

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Value

 

 

Capital

 

 

Gain

 

 

Deficit

 

 

Equity (Deficit)

 

Balance at March 31, 2023

 

 

20,409,130

 

 

$

20

 

 

$

688,492

 

 

$

263

 

 

$

(582,022

)

 

$

106,753

 

Vesting of restricted stock units

 

 

33,304

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of shares under Employee Stock Purchase Plan

 

 

54,082

 

 

 

 

 

 

144

 

 

 

 

 

 

 

 

 

144

 

Exercise of pre-funded warrants

 

 

211,840

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

2,814

 

 

 

 

 

 

 

 

 

2,814

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(214

)

 

 

 

 

 

(214

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(36,258

)

 

 

(36,258

)

Balance at June 30, 2023

 

 

20,708,356

 

 

$

20

 

 

$

691,450

 

 

$

49

 

 

$

(618,280

)

 

$

73,239

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at March 31, 2024

 

 

26,728,337

 

 

$

26

 

 

$

741,546

 

 

$

 

 

$

(726,515

)

 

$

15,057

 

Vesting of restricted stock units

 

 

27,180

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of shares under Employee Stock Purchase Plan

 

 

26,247

 

 

 

 

 

 

115

 

 

 

 

 

 

 

 

 

115

 

Issuance of restricted stock awards

 

 

28,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,803

 

 

 

 

 

 

 

 

 

1,803

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(23,327

)

 

 

(23,327

)

Balance at June 30, 2024

 

 

26,809,764

 

 

$

26

 

 

$

743,464

 

 

$

 

 

$

(749,842

)

 

$

(6,352

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8


 

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the six months ended June 30, 2024 and 2023

(in thousands, except share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

 

 

 

Number of

 

 

Par

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Value

 

 

Capital

 

 

Gain

 

 

Deficit

 

 

Equity (Deficit)

 

Balance at December 31, 2022

 

 

20,263,116

 

 

$

20

 

 

$

685,847

 

 

$

102

 

 

$

(558,233

)

 

$

127,736

 

Vesting of restricted stock units

 

 

144,327

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of shares under Employee Stock Purchase Plan

 

 

54,082

 

 

 

 

 

 

144

 

 

 

 

 

 

 

 

 

144

 

Exercise of pre-funded warrants

 

 

246,831

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

5,459

 

 

 

 

 

 

 

 

 

5,459

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(53

)

 

 

 

 

 

(53

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(60,047

)

 

 

(60,047

)

Balance at June 30, 2023

 

 

20,708,356

 

 

$

20

 

 

$

691,450

 

 

$

49

 

 

$

(618,280

)

 

$

73,239

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2023

 

 

26,448,678

 

 

$

26

 

 

$

739,443

 

 

$

 

 

$

(722,807

)

 

$

16,662

 

Vesting of restricted stock units

 

 

306,839

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of shares under Employee Stock Purchase Plan

 

 

26,247

 

 

 

 

 

 

115

 

 

 

 

 

 

 

 

 

115

 

Issuance of restricted stock awards

 

 

28,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

3,906

 

 

 

 

 

 

 

 

 

3,906

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(27,035

)

 

 

(27,035

)

Balance at June 30, 2024

 

 

26,809,764

 

 

$

26

 

 

$

743,464

 

 

$

 

 

$

(749,842

)

 

$

(6,352

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

9


 

SYROS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2024

 

 

2023

 

Operating activities

 

 

 

 

 

 

Net loss

 

$

(27,035

)

 

$

(60,047

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

665

 

 

 

1,288

 

Gain on disposal of property and equipment

 

 

(125

)

 

 

 

Non-cash lease expense

 

 

 

 

 

69

 

Stock-based compensation expense

 

 

3,906

 

 

 

5,459

 

Change in fair value of warrant liabilities

 

 

(31,360

)

 

 

(5,760

)

Net amortization of premiums and discounts on marketable securities

 

 

(302

)

 

 

(1,165

)

Amortization of debt-discount and accretion of deferred debt costs

 

 

273

 

 

 

281

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(503

)

 

 

502

 

Unbilled receivable

 

 

 

 

 

(62

)

Other long-term assets

 

 

132

 

 

 

3,119

 

Accounts payable

 

 

(4,075

)

 

 

282

 

Accrued expenses and other current liabilities

 

 

(1,812

)

 

 

(638

)

Deferred revenue

 

 

 

 

 

(2,145

)

Operating lease right-of-use-asset and liabilities

 

 

(529

)

 

 

(470

)

Net cash used in operating activities

 

 

(60,765

)

 

 

(59,287

)

Investing activities

 

 

 

 

 

 

Purchases of property and equipment

 

 

 

 

 

(234

)

Proceeds from the disposition of asset-held-for-sale

 

 

125

 

 

 

 

Purchases of marketable securities

 

 

(30,591

)

 

 

(50,968

)

Proceeds from the sale or maturities of marketable securities

 

 

30,893

 

 

 

58,377

 

Net cash provided by investing activities

 

 

427

 

 

 

7,175

 

Financing activities

 

 

 

 

 

 

Payments on financing lease obligations

 

 

 

 

 

(57

)

Proceeds from the issuance of common stock through Employee Stock Purchase Plan

 

 

115

 

 

 

144

 

Payment of issuance cost related to underwritten registered direct offering and at-the-market facility

 

 

(339

)

 

 

 

Net cash (used in) provided by financing activities

 

 

(224

)

 

 

87

 

Net decrease in cash, cash equivalents and restricted cash

 

 

(60,562

)

 

 

(52,025

)

Cash, cash equivalents and restricted cash (See reconciliation in Note 6)

 

 

 

 

 

 

Beginning of period

 

 

141,645

 

 

 

170,553

 

End of period

 

 

81,083

 

 

 

118,528

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

Cash paid for interest

 

$

2,632

 

 

$

2,173

 

See accompanying notes to unaudited condensed consolidated financial statements.

10


 

SYROS PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Nature of Business

Syros Pharmaceuticals, Inc. (the “Company”), a Delaware corporation formed in November 2011, is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

On April 6, 2023, the Company filed a universal shelf registration statement on Form S-3 (the “2023 Registration Statement”), with the Securities and Exchange Commission (the “SEC”) to register for sale from time to time up to $250.0 million of common stock, preferred stock, debt securities, warrants and/or units in one or more registered offerings. The 2023 Registration Statement was declared effective on April 28, 2023. Further, in April 2023, the Company entered into an at-the-market sales agreement (the “2023 Sales Agreement”) with Cowen and Company, LLC (“Cowen”) pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million through Cowen pursuant to the 2023 Registration Statement.

On October 2, 2023, the Company announced a strategic realignment to prioritize key development and pre-launch activities to advance tamibarotene for the treatment of newly diagnosed higher-risk myelodysplastic syndrome and newly diagnosed acute myeloid leukemia, and to stop further investment in the clinical development of SY-2101 (oral arsenic trioxide) for the treatment of newly diagnosed acute promyelocytic leukemia, as well as in the Company’s preclinical and discovery-stage programs. In connection with these decisions, the Company instituted certain expense reduction measures (the “Restructuring”), including a reduction of approximately 35% of the Company’s employee base excluding members of the Company’s drug discovery organization whose employment ended concurrently with the termination, effective October 16, 2023, of its collaboration with Pfizer, Inc. (“Pfizer”) related to the discovery, development and commercialization of novel therapies for sickle cell disease and beta thalassemia. The Restructuring was completed by February 2024.

The Company is subject to a number of risks similar to those of other late-stage clinical companies, including dependence on key individuals; risks inherent in the development and commercialization of medicines to treat human disease; competition from other companies, many of which are larger and better capitalized; risks relating to obtaining and maintaining necessary intellectual property protection; and the need to obtain adequate additional financing to fund the development of its product candidates. If the Company is unable to raise capital when needed or on favorable terms, it would be forced to delay, reduce, eliminate or out-license certain of its research and development programs or future commercialization rights to its product candidates.

The Company has incurred significant net operating losses in every year since its inception. It expects to continue to incur significant and increasing net operating losses for at least the next several years. As of June 30, 2024, the Company had an accumulated deficit of $749.8 million. The Company has not generated any revenues from product sales, has not completed the development of any product candidate and may never have a product candidate approved for commercialization. The Company has financed its operations to date primarily through a credit facility, the issuance of equity securities and through license and collaboration agreements. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative activities to support such research and development. The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company’s stockholders’ equity and working capital.

Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company’s ability to continue as a going concern.

Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company’s cost structure and operating plan. Management’s plans to alleviate its financing requirements include, among other things, pursuing one or more of the following steps, none of which can be guaranteed or is entirely within the Company’s control:

• raise funding through the issuance of the Company’s common or preferred stock;

• raise funding through debt financing; and

11


 

• raise funding through business development activities, including the potential sale of SY-2101-related assets.

 

If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful.

The Company’s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management’s assessment that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least 12 months from the issuance date of this Quarterly Report on Form 10-Q. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments that may result from the outcome of this uncertainty.

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of June 30, 2024, the results of its operations for the three and six months ended June 30, 2024 and 2023, statements of stockholders’ equity (deficit) for the three and six months ended June 30, 2024 and 2023, and statements of cash flows for the six months ended June 30, 2024 and 2023. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2024 are not necessarily indicative of the results for the year ending December 31, 2024, or for any future period.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, (i) Syros Securities Corporation, a Massachusetts corporation formed by the Company in December 2014 to exclusively engage in buying, selling and holding securities on its own behalf, (ii) Syros Pharmaceuticals (Ireland) Limited, an Irish limited liability company formed by the Company in January 2019, and (iii) Tyme Technologies, Inc., a Delaware corporation. All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and in developing these estimates, which include, but are not limited to, expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, valuation of warrant liabilities, stock-based compensation expense, accrued expenses, income taxes and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results may differ from those estimates or assumptions.

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making

12


 

decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is its chief executive officer. The Company and the chief operating decision maker view the Company’s operations and manage its business in one operating segment. The Company operates only in the United States.

Cash and Cash Equivalents

The Company considers all highly liquid instruments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents, which consist of money market funds that invest in U.S. Treasury obligations, as well as overnight repurchase agreements, are stated at fair value. The Company maintains its bank accounts in two major financial institutions.

Off-Balance Sheet Risk and Concentrations of Credit Risk

The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company’s investment policy, in order of priority, are safety and preservation of principal and liquidity of investments sufficient to meet cash flow requirements.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurement (“ASC 820”), established a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumption about the inputs that market participants would use in pricing the asset or liability. These are developed based on the best information available under the circumstances.

ASC 820 identified fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 established a three-tier fair value hierarchy that distinguishes between the following:

Level 1—Quoted market prices (unadjusted) in active markets for identical assets or liabilities.

Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3—Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying amounts reflected in the condensed consolidated balance sheets for cash and cash equivalents, prepaid expenses, other current assets, restricted cash, accounts payable, accrued expenses and deferred revenue approximate their respective fair values due to their short-term nature.

Property and Equipment

Property and equipment consists of computer equipment, furniture and fixtures and leasehold improvements, all of which are stated at cost, less accumulated depreciation. Expenditures for maintenance and repairs that do not improve or extend the lives of the respective assets are recorded to expense as incurred. Major betterments are capitalized as additions to property and equipment. Depreciation and amortization are recognized over the estimated useful lives of the assets using the straight-line method.

13


 

Impairment of Long-Lived Assets

The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the carrying values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying values of the assets exceed their fair value. The Company did not record any impairment losses during the three and six months ended June 30, 2024 and 2023.

Revenue Recognition

The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future.

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps:

(i)
identify the contract(s) with a customer;
(ii)
identify the performance obligations in the contract;
(iii)
determine the transaction price;
(iv)
allocate the transaction price to the performance obligations in the contract; and
(v)
recognize revenue when (or as) the entity satisfies a performance obligation.

The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

If the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, the Company records a contract asset, excluding any amounts presented as accounts receivable. The Company includes contract assets as unbilled accounts receivable on its consolidated balance sheets. The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses contract assets and accounts receivable for impairment and, to date, no impairment losses have been recorded.

From time to time, the Company may enter into agreements that are within the scope of ASC 606. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees or prepaid research and development services; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Each of these payments results in license and collaboration revenues, except for revenues from royalties on net sales of licensed products, which will be classified as royalty revenues.

The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above.

14


 

Research and Development

Expenditures relating to research and development are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with the development of the Company’s product candidates. Research and development costs include salaries and benefits, materials and supplies, external research, preclinical and clinical development expenses, stock-based compensation expense and facilities costs. Facilities costs primarily include the allocation of rent, utilities, depreciation and amortization.

In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, even when there is no alternative future use for the research and development, until related goods or services are provided.

The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the work being performed, including the phase or completion of the event, invoices received and costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.

The Company may in-license the rights to develop and commercialize product candidates. For each in-license transaction, the Company evaluates whether it has acquired processes or activities along with inputs that would be sufficient to constitute a “business” as defined under U.S. GAAP. A “business” as defined under U.S. GAAP consists of inputs and processes applied to those inputs that have the ability to create outputs. Although businesses usually have outputs, outputs are not required for an integrated set of activities to qualify as a business. When the Company determines that it has not acquired sufficient processes or activities to constitute a business, any up-front payments, as well as milestone payments, are immediately expensed as acquired research and development in the period in which they are incurred.

Warrants

The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (“ASC 815-40”). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

Stock-Based Compensation Expense

The Company accounts for its stock-based compensation awards in accordance with ASC 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees and directors, including grants of restricted stock units and stock option awards, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model. The Company estimates its expected stock volatility based on its historical volatility. The expected term of the Company’s stock options granted to employees has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The Company uses the contractual term in determining the expected term of the stock options granted to non-employees. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The Company uses the value of its common stock at the grant date to determine the fair value of restricted stock awards.

15


 

The Company expenses the fair value of its stock-based awards to employees and non-employees on a straight-line basis over the associated service period, which is generally the vesting period. The Company accounts for forfeitures as they occur instead of estimating forfeitures at the time of grant. Ultimately, the actual expense recognized over the vesting period will be for only those options that vest.

Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period.

For stock-based awards that contain performance-based milestones, the Company records stock-based compensation expense in accordance with the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.

Income Taxes

The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position.

Net Loss per Share

Basic net earnings per share applicable to common stockholders is calculated by dividing net earnings applicable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net earnings per share applicable to common stockholders is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method and the if-converted method. For purposes of the calculation of dilutive net loss per share applicable to common stockholders, stock options, unvested restricted stock units, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share applicable to common stockholders, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.

The following outstanding pre-funded warrants as of June 30, 2024 and 2023 were included in the basic and diluted net loss per share calculation (refer to Note 10):

 

 

 

As of June 30,

 

 

 

2024

 

 

2023

 

2020 Pre-Funded Warrants, issued in the 2020 Private Placement

 

 

100,000

 

 

 

100,000

 

2022 Pre-Funded Warrants, issued in the 2022 Private Placement

 

 

7,179,819

 

 

 

7,279,819

 

2023 Pre-Funded Warrants, issued in December 2023 registered direct offering

 

 

5,242,588

 

 

 

 

Total

 

 

12,522,407

 

 

 

7,379,819

 

 

 

 

 

 

 

 

The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

 

 

As of June 30,

 

 

 

2024

 

 

2023

 

Stock options

 

 

1,533,059

 

 

 

1,747,357

 

Unvested restricted stock units

 

 

3,072,224

 

 

 

2,321,582

 

Warrants*

 

 

14,142,298

 

 

 

14,142,298

 

Total

 

 

18,747,581

 

 

 

18,211,237

 

* As of June 30, 2024 and 2023, this is comprised of 2,754 warrants to purchase common stock issued in connection with the execution and first draw of the Company’s loan agreement in February 2020 (refer to Note 7), 1,738 warrants to purchase common stock issued in connection with the second draw on this loan agreement in December 2020 (refer to

16


 

Note 7), 282,809 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 10), 13,813,912 warrants to purchase common stock issued in connection with the private placement in September 2022 (refer to Note 10), and 41,085 warrants to purchase common stock that were issued upon the assumption and conversion of warrants in connection with the acquisition of Tyme Technologies, Inc.

3. Collaboration and Research Arrangements

During the three and six months ended June 30, 2023, the Company recognized revenue of $2.8 million and $5.8 million, respectively, under a license and collaboration agreement with Global Therapeutics, Inc, now a subsidiary of Pfizer. As of June 30, 2023, the Company had deferred revenue outstanding under that agreement of approximately $2.2 million, all of which is classified as deferred revenue, current portion on the Company’s condensed consolidated balance sheet. As the agreement was terminated in October 2023, no revenue was recognized during the three and six month periods ended June 30, 2024.

4. Cash and Cash Equivalents

Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. Unrealized gains or losses are included in accumulated other comprehensive loss. Premiums or discounts from par value are amortized to interest income over the life of the underlying security.

Cash and cash equivalents consisted of the following as of June 30, 2024 and December 31, 2023 (in thousands):

 

 

 

 

 

Unrealized

 

 

Unrealized

 

 

Fair

 

June 30, 2024

 

Amortized Cost

 

 

Gains

 

 

Losses

 

 

Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

 

$

78,964

 

 

$

 

 

$

 

 

$

78,964

 

Total:

 

$

78,964

 

 

$

 

 

$

 

 

$

78,964

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized

 

 

Unrealized

 

 

Fair

 

December 31, 2023

 

Amortized Cost

 

 

Gains

 

 

Losses

 

 

Value

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

 

$

139,526

 

 

$

 

 

$

 

 

$

139,526

 

Total

 

$

139,526

 

 

$

 

 

$

 

 

$

139,526

 

 

5. Fair Value Measurements

Assets and liabilities measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 were as follows (in thousands):

 

 

 

 

 

Active

 

 

Observable

 

 

Unobservable

 

 

 

 

 

 

Markets

 

 

Inputs

 

 

Inputs

 

Description

 

June 30, 2024

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

 

$

78,964

 

 

$

78,964

 

 

$

 

 

$

 

Total

 

$

78,964

 

 

$

78,964

 

 

$

 

 

$

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

30,387

 

 

$

 

 

$

 

 

$

30,387

 

Total

 

$

30,387

 

 

$

 

 

$

 

 

$

30,387

 

 

17


 

 

 

 

 

 

Active

 

 

Observable

 

 

Unobservable

 

 

 

 

 

 

Markets

 

 

Inputs

 

 

Inputs

 

Description

 

December 31, 2023

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and money market funds

 

$

139,526

 

 

$

139,526

 

 

$

 

 

$

 

Total

 

$

139,526

 

 

$

139,526

 

 

$

 

 

$

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

61,747

 

 

$

 

 

$

 

 

$

61,747

 

Total

 

$

61,747

 

 

$

 

 

$

 

 

$

61,747

 

Assumptions Used in Determining Fair Value of Warrants

The Company issued warrants to purchase an aggregate of up to 13,813,912 shares of common stock in connection with a private placement in September 2022 (the “2022 Warrants”) and warrants to purchase an aggregate of up to 282,809 shares of common stock in connection with a private placement in December 2020 (the “2020 Warrants”). The Company accounted for the 2022 Warrants and 2020 Warrants as liabilities. The Company recorded the fair value of these warrants upon issuance using the Black-Scholes valuation model and is required to revalue these warrants at each reporting date with any changes in fair value recorded on the Company's statement of operations. The valuation of the 2022 Warrants and 2020 Warrants is considered under Level 3 of the fair value hierarchy and influenced by the fair value of the underlying common stock of the Company.

A summary of the Black Scholes pricing model assumptions used to record the fair value of the warrants is as follows:

 

 

June 30, 2024

 

 

 

December 31, 2023

Stock price

 

$

5.16

 

 

 

$

7.79

 

 

Average risk-free interest rate

 

 

4.51

 

%

 

 

3.96

 

%

Average expected life (in years)

 

 

3.17

 

 

 

 

3.67

 

 

Average expected volatility

 

 

84.59

 

%

 

 

87.63

 

%

Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis

The following table reflects the change in the Company’s Level 3 warrant liabilities for the six months ended June 30, 2024 and the year ended December 31, 2023 (in thousands):

 

 

June 30, 2024

 

 

 

December 31, 2023

 

Fair value of warrant liabilities as of beginning of period

 

$

61,747

 

 

 

$

24,472

 

Change in fair value

 

 

(31,360

)

 

 

 

37,275

 

Fair value of warrant liabilities as of end of period

 

$

30,387

 

 

 

$

61,747

 

 

6. Restricted Cash

As of each of June 30, 2024 and December 31, 2023, the Company had $2.1 million in restricted cash, which was classified as long-term on the Company’s condensed consolidated balance sheets, and all of which was attributable to the lease with respect to the Company's corporate headquarters (the “HQ Lease”) (See Note 9).

In connection with the execution of the HQ Lease, the Company was required to provide the landlord with a letter of credit in the amount of $3.1 million that will expire 95 days after expiration or early termination of the HQ Lease. Pursuant to the HQ Lease, the Company exercised its right to reduce the amount of the letter of credit to $2.1 million during the year ended December 31, 2023.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the amounts shown in the Company’s condensed consolidated statement of cash flows as of June 30, 2024 and 2023 (in thousands):

18


 

 

 

June 30,

 

 

 

2024

 

 

2023

 

Cash and cash equivalents

 

$

78,964

 

 

$

115,442

 

Restricted cash

 

$

2,119

 

 

 

3,086

 

Total cash, cash equivalents and restricted cash

 

$

81,083

 

 

$

118,528

 

 

7. Oxford Finance Loan Agreement

On February 12, 2020, the Company entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Oxford Finance LLC (the “Lender”). Pursuant to the terms of an amendment dated May 9, 2024 (the “Fourth Loan Amendment”), the Loan Agreement was modified to increase the aggregate amount of term loans available to the Company from $60.0 million to $100.0 million.